Get the Stockscreener App
2.38
0.00%
0.00
Cytomed Therapeutics Ltd Stock (GDTC) Forecast
The Cytomed Therapeutics Ltd (GDTC) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $1.4759, representing a -37.99% decrease from the current price of $2.38. The highest analyst price target is $1.8059, and the lowest is $1.146.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GDTC Price Target
Average 3.5886
(+50.78% Upside)
Is Cytomed Therapeutics Ltd (GDTC) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.09 | Neutral |
| STOCH(9,6) | 46.26 | Neutral |
| STOCHRSI(14) | 68.78 | Neutral |
| MACD(12,26) | -0.0953 | Sell |
| ADX(14) | 12.32 | Neutral |
| William %R | -48.46 | Neutral |
| CCI(14) | -40.33 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.3218
Buy
|
2.3668
Buy
|
| MA20 |
2.4715
Sell
|
2.4437
Sell
|
| MA50 |
2.6108
Sell
|
2.5406
Sell
|
| MA100 |
2.5854
Sell
|
2.5139
Sell
|
| MA200 |
2.2535
Buy
|
2.5142
Sell
|
Buy: 3
Sell: 7
Neutral: 0
Summary: Sell
According to our latest analysis, GDTC could be considered a Moderate Sell, with 17 technical analysis indicators signaling 3 Buy signals, 8 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on GDTC, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 44.09 indicates that GDTC is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 46.26 indicates that GDTC is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 68.78 indicates that GDTC is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 12.32 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -40.33 indicates that GDTC is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term GDTC price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Cytomed Therapeutics Ltd financial reports and earnings history, Cytomed Therapeutics Ltd (GDTC) stock could reach $0.629 by 2030, $12.55 by 2040 and $18.88 by 2050. See the projected annual prices until 2050 of the Cytomed Therapeutics Ltd stock below:
- Cytomed Therapeutics Ltd (GDTC) is expected to reach an average price of $5.0079 in 2035, with a high prediction of $5.121 and a low estimate of $5.0879. This indicates an $110.42% rise from the last recorded price of $2.38.
- Cytomed Therapeutics Ltd (GDTC) stock is projected to chart a bullish course in 2040, with an average price target of $12.80, representing an $437.79% surge from its current level. The forecast ranges from a conservative $7.7233 to a sky-high $12.55.
- Our analysts predict Cytomed Therapeutics Ltd (GDTC) to jump 611.55% by 2045, soaring from $17.15 to an average price of $16.93, potentially reaching $17.25. While $17.15 is the low estimate, the potential upside is significant.
- Cytomed Therapeutics Ltd (GDTC) stock is expected to climb by 2050, reaching an average of $19.09, a $702.29% jump from its current level. However, a wide range of estimates exists, with high and low targets of $18.88 and $19.03, respectively, highlighting the market's uncertainty.
Cytomed Therapeutics Ltd Stock (GDTC) Year by Year Forecast
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2025
Cytomed Therapeutics Ltd Stock (GDTC) is expected to reach an average price of $3.5886 in 2025, with a high prediction of $7.0983 and a low estimate of $0.0788. This indicates an +50.78% rise from the last recorded price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $1.456 | $1.146 | $1.8059 | -38.82% |
| June, 2025 | $1.3119 | $1.2089 | $1.5524 | -44.88% |
| July, 2025 | $1.0429 | $0.9029 | $1.87 | -56.18% |
| August, 2025 | $0.4247 | $0.0788 | $2.5188 | -82.15% |
| September, 2025 | $0.6765 | $0.3165 | $1.3965 | -71.58% |
| October, 2025 | $1.6112 | $0.3694 | $7.0983 | -32.30% |
| November, 2025 | $1.863 | $1.2843 | $2.353 | -21.72% |
| December, 2025 | $1.3977 | $1.1889 | $2.0888 | -41.27% |
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2026
The predicted value for Cytomed Therapeutics Ltd (GDTC) in 2026 is set at an average of $1.9009. Estimates vary from a peak of $3.7107 to a trough of $0.0912, indicating an -20.13% surge from the present price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.5095 | $1.2536 | $1.8966 | -36.58% |
| February, 2026 | $1.8113 | $1.3225 | $2.0454 | -23.90% |
| March, 2026 | $1.8231 | $1.7081 | $2.4842 | -23.40% |
| April, 2026 | $2.4078 | $1.2948 | $2.8278 | +1.17% |
| May, 2026 | $2.1496 | $2.0596 | $3.7107 | -9.68% |
| June, 2026 | $0.7513 | $0.2213 | $2.5625 | -68.43% |
| July, 2026 | $0.4261 | $0.3002 | $1.0043 | -82.10% |
| August, 2026 | $0.4178 | $0.342 | $1.0019 | -82.44% |
| September, 2026 | $0.5752 | $0.4437 | $0.7067 | -75.83% |
| October, 2026 | $0.4917 | $0.0912 | $1.3783 | -79.34% |
| November, 2026 | $0.6041 | $0.6073 | $0.5341 | -74.62% |
| December, 2026 | $0.023 | $0.317 | $0.4357 | -99.03% |
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Cytomed Therapeutics Ltd (GDTC) is $3.0597, with a high forecast of $6.0224 and a low forecast of $0.0969. This indicates an +28.56% increase from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.1807 | $0.0969 | $6.0224 | -50.39% |
| February, 2027 | $0.3983 | $0.1583 | $1.3095 | -83.26% |
| March, 2027 | $0.4154 | $0.2554 | $0.8004 | -82.55% |
| April, 2027 | $0.6731 | $0.3437 | $0.9048 | -71.72% |
| May, 2027 | $1.1996 | $0.4525 | $1.5313 | -49.60% |
| June, 2027 | $0.6678 | $0.5879 | $1.3402 | -71.94% |
| July, 2027 | $1.7655 | $0.3873 | $2.8161 | -25.82% |
| August, 2027 | $0.9532 | $0.9132 | $2.2149 | -59.95% |
| September, 2027 | $0.4797 | $0.1786 | $1.0826 | -79.84% |
| October, 2027 | $0.1521 | $0.3765 | $0.2138 | -93.61% |
| November, 2027 | $0.2444 | $0.3026 | $0.216 | -89.73% |
| December, 2027 | $1.2641 | $0.1361 | $1.0141 | -46.89% |
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2028
In 2028, Cytomed Therapeutics Ltd (GDTC) is projected to reach an average price of $2.4767, with a high projection of $4.9466 and a low estimate of $0.0068. This indicates an +4.06% rise from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.8306 | $1.2382 | $1.3707 | -23.09% |
| February, 2028 | $1.527 | $1.7529 | $1.6488 | -35.84% |
| March, 2028 | $0.5275 | $0.5675 | $4.9466 | -77.83% |
| April, 2028 | $0.224 | $0.1898 | $0.266 | -90.59% |
| May, 2028 | $0.6245 | $0.5981 | $0.52 | -73.76% |
| June, 2028 | $0.461 | $0.4669 | $0.231 | -80.63% |
| July, 2028 | $0.1074 | $0.3714 | $0.3151 | -95.49% |
| August, 2028 | $0.018 | $0.0243 | $0.5785 | -99.24% |
| September, 2028 | $0.6056 | $0.1608 | $1.0256 | -74.56% |
| October, 2028 | $0.3991 | $0.3091 | $1.9215 | -83.23% |
| November, 2028 | $0.9714 | $0.0068 | $0.825 | -59.18% |
| December, 2028 | $1.2079 | $1.1462 | $1.0246 | -49.25% |
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2029
The 2029 price forecast for Cytomed Therapeutics Ltd Stock (GDTC) is $2.1217 on average, with a high prediction of $3.8707 and a low estimate of $0.3727. This represents an -10.85% decrease from the previous price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.0384 | $1.1002 | $1.0243 | -56.37% |
| February, 2029 | $0.9187 | $0.8949 | $0.9425 | -61.40% |
| March, 2029 | $2.7729 | $2.3853 | $2.1676 | +16.51% |
| April, 2029 | $2.8335 | $2.8756 | $2.7635 | +19.05% |
| May, 2029 | $2.1417 | $2.4817 | $2.6521 | -10.01% |
| June, 2029 | $0.9322 | $1.2722 | $3.8707 | -60.83% |
| July, 2029 | $1.6628 | $1.2398 | $1.3528 | -30.14% |
| August, 2029 | $1.581 | $1.5933 | $1.5441 | -33.57% |
| September, 2029 | $1.2715 | $1.4586 | $1.2939 | -46.58% |
| October, 2029 | $0.9797 | $0.9221 | $1.1291 | -58.84% |
| November, 2029 | $1.1603 | $1.0813 | $0.9371 | -51.25% |
| December, 2029 | $0.0108 | $0.3727 | $1.0268 | -99.55% |
Cytomed Therapeutics Ltd Stock (GDTC) Price Forecast for 2030
Cytomed Therapeutics Ltd Stock (GDTC) is expected to reach an average price of $2.0783 in 2030, with a high forecast of $3.8782 and a low forecast of $0.2784. This signifies an -12.68% decrease from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.7714 | $0.2784 | $0.629 | -67.59% |
| February, 2030 | $2.1396 | $1.8643 | $1.8546 | -10.10% |
| March, 2030 | $1.7601 | $1.9975 | $1.8348 | -26.05% |
| April, 2030 | $1.8007 | $1.8907 | $1.7852 | -24.34% |
| May, 2030 | $3.5712 | $1.6536 | $3.3212 | +50.05% |
| June, 2030 | $4.0858 | $3.5323 | $3.6259 | +71.67% |
| July, 2030 | $3.7917 | $3.9693 | $3.8782 | +59.31% |
| August, 2030 | $2.6663 | $2.7063 | $3.1011 | +12.03% |
| September, 2030 | $2.311 | $2.2897 | $2.0775 | -2.90% |
| October, 2030 | $2.6468 | $2.6722 | $2.5682 | +11.21% |
| November, 2030 | $2.4315 | $2.4503 | $2.218 | +2.16% |
| December, 2030 | $2.0261 | $2.2901 | $2.2726 | -14.87% |
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):